Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 3 |
2017 | 3 |
2019 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Mol Cancer Ther. 2019 Jun;18(6):1036-1044. doi: 10.1158/1535-7163.MCT-18-1206. Epub 2019 Apr 24.
Mol Cancer Ther. 2019.
PMID: 31018997
Free PMC article.
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.
Joshi S, Durden DL.
Joshi S, et al.
J Oncol. 2019 Feb 3;2019:5245034. doi: 10.1155/2019/5245034. eCollection 2019.
J Oncol. 2019.
PMID: 30853982
Free PMC article.
Review.
Item in Clipboard
Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.
Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL.
Erdreich-Epstein A, et al.
Oncotarget. 2016 Nov 18;8(32):52193-52210. doi: 10.18632/oncotarget.13386. eCollection 2017 Aug 8.
Oncotarget. 2016.
PMID: 28881723
Free PMC article.
Item in Clipboard
Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype.
Joshi S, Singh AR, Wong SS, Zulcic M, Jiang M, Pardo A, Selman M, Hagood JS, Durden DL.
Joshi S, et al.
PLoS One. 2017 Aug 17;12(8):e0182851. doi: 10.1371/journal.pone.0182851. eCollection 2017.
PLoS One. 2017.
PMID: 28817691
Free PMC article.
Item in Clipboard
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG.
Andrews FH, et al.
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1072-E1080. doi: 10.1073/pnas.1613091114. Epub 2017 Jan 30.
Proc Natl Acad Sci U S A. 2017.
PMID: 28137841
Free PMC article.
Item in Clipboard
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
Singh AR, et al.
Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5.
Mol Cancer Ther. 2016.
PMID: 27496136
Free PMC article.
Item in Clipboard
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL.
Singh AR, et al.
PLoS One. 2016 Mar 3;11(3):e0150836. doi: 10.1371/journal.pone.0150836. eCollection 2016.
PLoS One. 2016.
PMID: 26938241
Free PMC article.
Item in Clipboard
Cite
Cite